TY - JOUR
AU - Simonis, Alexander
AU - Kreer, Christoph
AU - Albus, Alexandra
AU - Rox, Katharina
AU - Yuan, Biao
AU - Holzmann, Dmitriy
AU - Wilms, Joana A.
AU - Zuber, Sylvia
AU - Kottege, Lisa
AU - Winter, Sandra
AU - Meyer, Meike
AU - Schmitt, Kristin
AU - Gruell, Henning
AU - Theobald, Sebastian J.
AU - Hellmann, Anna-Maria
AU - Meyer, Christina
AU - Ercanoglu, Meryem Seda
AU - Cramer, Nina
AU - Munder, Antje
AU - Hallek, Michael
AU - Fätkenheuer, Gerd
AU - Koch, Manuel
AU - Seifert, Harald
AU - Rietschel, Ernst
AU - Marlovits, Thomas
AU - van Koningsbruggen-Rietschel, Silke
AU - Klein, Florian
AU - Rybniker, Jan
TI - Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa
JO - Cell
VL - 186
IS - 23
SN - 0092-8674
CY - New York, NY
PB - Elsevier
M1 - PUBDB-2024-00412
SP - 5098 - 5113
PY - 2023
N1 - Waiting for fulltext
AB - Drug-resistant Pseudomonas aeruginosa (PA) poses an emerging threat to human health with urgent need for alternative therapeutic approaches. Here, we deciphered the B cell and antibody response to the virulence-associated type III secretion system (T3SS) in a cohort of patients chronically infected with PA. Single-cell analytics revealed a diverse B cell receptor repertoire directed against the T3SS needle-tip protein PcrV, enabling the production of monoclonal antibodies (mAbs) abrogating T3SS-mediated cytotoxicity. Mechanistic studies involving cryoelectron microscopy identified a surface-exposed C-terminal PcrV epitope as the target of highly neutralizing mAbs with broad activity against drug-resistant PA isolates. These anti-PcrV mAbs were as effective as treatment with conventional antibiotics in vivo. Our study reveals that chronically infected patients represent a source of neutralizing antibodies, which can be exploited as therapeutics against PA.
LB - PUB:(DE-HGF)16
C6 - pmid:37918395
UR - <Go to ISI:>//WOS:001116377000001
DO - DOI:10.1016/j.cell.2023.10.002
UR - https://bib-pubdb1.desy.de/record/601922
ER -